BR9914097A - Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto - Google Patents
Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do compostoInfo
- Publication number
- BR9914097A BR9914097A BR9914097-7A BR9914097A BR9914097A BR 9914097 A BR9914097 A BR 9914097A BR 9914097 A BR9914097 A BR 9914097A BR 9914097 A BR9914097 A BR 9914097A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- viral infection
- preparing
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 208000036142 Viral infection Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000009385 viral infection Effects 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- -1 nucleoside phosphoramidates Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000008298 phosphoramidates Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA E MéTODO DE PROFILAXIA OU TRATAMENTO DE UMA INFECçãO VIRAL E PROCESSO PARA PREPARAçãO DO COMPOSTO". Composto químico compreendendo fosforamidatos nucleosídeo, sua preparação e sua utilização terapêutica no tratamento de infecção viral, especialmente HIV e HBV são divulgadas. Os compostos contêm uma fração de análogo de adenina substituído compreendendo 2-amino-6-(ciclopropilamino)-9H-purin-9-il. Os compostos demonstram ambas atividade antiviral e estabilidade ácida. Sais e ésteres da fosforamidatos são incluídos. Um composto representativo é (1S, 4R), -4-[2-amino-6-(ciclopropilamino)-9H-purin-9-il]-2-ciclopenteno-1-meta nol-5'-[fenil-(metoxi-L-alaninila)]-fosforamidato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821058.6A GB9821058D0 (en) | 1998-09-28 | 1998-09-28 | Chemical compound |
| PCT/GB1999/003207 WO2000018775A1 (en) | 1998-09-28 | 1999-09-27 | Antiviral purine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9914097A true BR9914097A (pt) | 2001-07-31 |
Family
ID=10839578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9914097-7A BR9914097A (pt) | 1998-09-28 | 1999-09-27 | Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6638919B2 (pt) |
| EP (1) | EP1117669B1 (pt) |
| JP (1) | JP2002525374A (pt) |
| KR (1) | KR20010085855A (pt) |
| CN (1) | CN1328565A (pt) |
| AR (1) | AR042368A1 (pt) |
| AT (1) | ATE231874T1 (pt) |
| AU (1) | AU762757B2 (pt) |
| BR (1) | BR9914097A (pt) |
| CA (1) | CA2345672A1 (pt) |
| DE (1) | DE69905181T2 (pt) |
| DK (1) | DK1117669T3 (pt) |
| ES (1) | ES2192081T3 (pt) |
| GB (1) | GB9821058D0 (pt) |
| GC (1) | GC0000174A (pt) |
| GT (1) | GT199900166A (pt) |
| HU (1) | HUP0103641A3 (pt) |
| IL (1) | IL141959A0 (pt) |
| MA (1) | MA26694A1 (pt) |
| MY (1) | MY121839A (pt) |
| NO (1) | NO20011198L (pt) |
| NZ (1) | NZ510506A (pt) |
| PA (1) | PA8483101A1 (pt) |
| PE (1) | PE20001072A1 (pt) |
| PL (1) | PL346905A1 (pt) |
| PT (1) | PT1117669E (pt) |
| TN (1) | TNSN99183A1 (pt) |
| TR (1) | TR200100864T2 (pt) |
| TW (1) | TWI243176B (pt) |
| WO (1) | WO2000018775A1 (pt) |
| ZA (1) | ZA200102170B (pt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115590B1 (en) * | 1999-02-12 | 2006-10-03 | University College Cardiff Consultants Limited | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents |
| BR0012676A (pt) | 1999-07-22 | 2003-07-01 | Newbiotics Inc | Métodos para tratamento de tumores resistentes a terapia |
| PE20010915A1 (es) * | 1999-12-10 | 2001-09-29 | Glaxo Group Ltd | Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales |
| US20030045508A1 (en) * | 1999-12-10 | 2003-03-06 | Daluge Susan Mary | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral |
| CN1291994C (zh) † | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
| US8716548B2 (en) | 2002-02-20 | 2014-05-06 | The Procter & Gamble Company | Disposable absorbent article designed to facilitate an easy change |
| US20030158532A1 (en) | 2002-02-20 | 2003-08-21 | Magee Luke R. | Disposable absorbent article designed to facilitate an easy intuitive change |
| US7094768B2 (en) | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| US7425547B2 (en) | 2002-09-30 | 2008-09-16 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
| GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
| CA2571079A1 (en) * | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| CA2570634A1 (en) * | 2004-06-30 | 2006-02-02 | Eli Lilly And Company | 1 (indole-6-carbonyl-d-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine d-tartrate |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| PL217694B1 (pl) | 2010-10-19 | 2014-08-29 | Inst Chemii Bioorg Polskiej Akademii Nauk | Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna |
| CN103842369A (zh) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
| TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物 |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| AP3913A (en) | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
| HUE029038T2 (en) | 2012-05-25 | 2017-01-30 | Janssen Sciences Ireland Uc | Uracil spirooxetan nucleosides |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| SG11201502750UA (en) | 2012-10-08 | 2015-06-29 | Idenix Pharmaceuticals Inc | 2'-chloro nucleoside analogs for hcv infection |
| EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| NZ729172A (en) | 2013-01-31 | 2018-06-29 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
| CN113444046B (zh) * | 2016-07-20 | 2023-10-27 | 纳莹(上海)生物科技有限公司 | 一种荧光探针及其制备方法和用途 |
| US20190185507A1 (en) * | 2016-08-19 | 2019-06-20 | Sandoz Ag | Sofosbuvir Derivatives for the Treatment of Hepatitis C |
| RU2659388C1 (ru) * | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| TW202019941A (zh) | 2018-07-27 | 2020-06-01 | 日商富士軟片股份有限公司 | 環丁基嘌呤衍生物或其鹽 |
| TW202019942A (zh) * | 2018-07-27 | 2020-06-01 | 日商富士軟片股份有限公司 | 環戊烯嘌呤衍生物或其鹽 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK663588A (da) | 1987-11-30 | 1989-05-31 | Beecham Group Plc | Purinderivater |
| CA2001715C (en) * | 1988-11-14 | 1999-12-28 | Muzammil M. Mansuri | Carbocyclic nucleosides and nucleotides |
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| EP0468119A1 (en) * | 1990-07-24 | 1992-01-29 | Merrell Dow Pharmaceuticals Inc. | Novel carbocyclic analogs of certain nucleosides |
| SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| EP0719273B1 (en) | 1993-09-17 | 2010-11-03 | Gilead Sciences, Inc. | Nucleotide analogs |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| DE69729887T2 (de) | 1996-10-16 | 2005-07-28 | ICN Pharmaceuticals, Inc., Costa Mesa | Purin-L-Nukleoside, Analoga und deren Verwendung |
-
1998
- 1998-09-28 GB GBGB9821058.6A patent/GB9821058D0/en not_active Ceased
-
1999
- 1999-09-22 TW TW088116280A patent/TWI243176B/zh active
- 1999-09-24 MA MA25787A patent/MA26694A1/fr unknown
- 1999-09-27 PT PT99949151T patent/PT1117669E/pt unknown
- 1999-09-27 PL PL99346905A patent/PL346905A1/xx unknown
- 1999-09-27 ES ES99949151T patent/ES2192081T3/es not_active Expired - Lifetime
- 1999-09-27 ZA ZA200102170A patent/ZA200102170B/en unknown
- 1999-09-27 AU AU62138/99A patent/AU762757B2/en not_active Ceased
- 1999-09-27 PE PE1999000978A patent/PE20001072A1/es not_active Application Discontinuation
- 1999-09-27 EP EP99949151A patent/EP1117669B1/en not_active Expired - Lifetime
- 1999-09-27 WO PCT/GB1999/003207 patent/WO2000018775A1/en not_active Ceased
- 1999-09-27 DK DK99949151T patent/DK1117669T3/da active
- 1999-09-27 AT AT99949151T patent/ATE231874T1/de not_active IP Right Cessation
- 1999-09-27 NZ NZ510506A patent/NZ510506A/en unknown
- 1999-09-27 CN CN99813577A patent/CN1328565A/zh active Pending
- 1999-09-27 IL IL14195999A patent/IL141959A0/xx unknown
- 1999-09-27 HU HU0103641A patent/HUP0103641A3/hu unknown
- 1999-09-27 JP JP2000572234A patent/JP2002525374A/ja not_active Withdrawn
- 1999-09-27 DE DE69905181T patent/DE69905181T2/de not_active Expired - Fee Related
- 1999-09-27 BR BR9914097-7A patent/BR9914097A/pt not_active IP Right Cessation
- 1999-09-27 CA CA002345672A patent/CA2345672A1/en not_active Abandoned
- 1999-09-27 MY MYPI99004169A patent/MY121839A/en unknown
- 1999-09-27 PA PA19998483101A patent/PA8483101A1/es unknown
- 1999-09-27 KR KR1020017003894A patent/KR20010085855A/ko not_active Ceased
- 1999-09-27 TR TR2001/00864T patent/TR200100864T2/xx unknown
- 1999-09-27 TN TNTNSN99183A patent/TNSN99183A1/fr unknown
- 1999-09-28 GT GT199900166A patent/GT199900166A/es unknown
- 1999-09-28 GC GCP1999302 patent/GC0000174A/en active
- 1999-09-28 AR ARP990104876A patent/AR042368A1/es not_active Application Discontinuation
-
2001
- 2001-03-08 NO NO20011198A patent/NO20011198L/no unknown
- 2001-03-27 US US09/825,554 patent/US6638919B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY121839A (en) | Antiviral purine derivatives | |
| ATE123285T1 (de) | Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate. | |
| MY103760A (en) | Therapeutic nucleosides | |
| FI20001231A7 (fi) | 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina | |
| TW371660B (en) | Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections | |
| IE892061L (en) | Therapeutic nucleosides | |
| AU644095B2 (en) | Antiviral compounds | |
| DE3689976D1 (de) | Therapeutische Nucleoside und deren Herstellung. | |
| WO1993017020A3 (en) | Therapeutic nucleosides | |
| ES2065914T3 (es) | Nucleosidos terapeuticos. | |
| ATE74603T1 (de) | Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
| HUT77222A (hu) | Antivirális hatású (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol borostyánkősavsó, eljárás előállítására és az azt tartalmazó gyógyszerkészítmény | |
| KR870006900A (ko) | 항바이러스 조성물 | |
| KR880012628A (ko) | 치료학적인 뉴클레오시드 | |
| HUP0002754A2 (hu) | (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek | |
| IL90959A0 (en) | Guanine derivatives,their preparation and pharmaceutical compositions containing them | |
| DK0479822T3 (da) | Terapeutiske nucleosider | |
| ECSP993155A (es) | Compuestos quimicos | |
| EP0317728A3 (en) | Use of 9-(beta-d-arabinofuranosyl) adenine derivatives for the preparation of pharmaceutical compositions for the treatment of aids | |
| FI943295A0 (fi) | Piliostigma thonningii -uutteet, niiden käyttö ja Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit niitä sisältävät formuloinnit | |
| MX9709788A (es) | Analogos de nucleotidos para tratamiento topico de enfermedades proliferativas de la piel. | |
| GEP19970908B (en) | Esters of 9-(2-hydroxyethoxymethyl)guanine having antiviral properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050101630/RJ DE 21/09/2005. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1947 DE 29 -- 04 - 2008. |